panitumumab
amgen,takeda
['colorectal', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'improve ', 'panitumumab', 'rectal']
randomized intermittent or continuous panitumumab plus folfiri (folfiri/pani) for first-line treatment of patients (pts) with ras/braf wild-type (wt) metastatic colorectal cancer (mcrc): the improve study. talk by dr. antonio avallone, md #asco22 #crcsm 
Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology